CHICAGO, IL
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)FOUNDATION FOR SARCOIDOSIS RESEARCH, founded in 2000, is a mid-sized nonprofit in the Philanthropy & Grantmaking sector that reported $13.6M in total revenue in fiscal year 2024. Revenue surged 428% from the prior year, signaling strong growth momentum. The organization ran a surplus of $10.2M, a strong 75% operating margin.
THE FOUNDATION FOR SARCOIDOSIS RESEARCH (FSR) IS THE LEADING INTERNATIONAL ORGANIZATION DEDICATED TO FINDING A CURE FOR SARCOIDOSIS AND IMPROVING CARE FOR SARCOIDOSIS PATIENTS THROUGH RESEARCH, EDUCATION, AND SUPPORT. SINCE ITS ESTABLISHMENT IN 2000, FSR HAS FOSTERED OVER $7.5 MILLION IN SARCOIDOSIS SPECIFIC RESEARCH EFFORTS.
PATIENT AND CLINICIAN SUPPORT AND PROGRAMMING:FSR PROVIDES PATIENTS WITH DIRECT SUPPORT THROUGH OUR PEER-LED TRAINED VOLUNTEER COMMUNITY GROUPS, SUPPORT GROUPS, OUR ONE-ONE-ONE PATIENT NAVIGATOR...
PATIENT AND CLINICIAN SUPPORT AND PROGRAMMING:FSR PROVIDES PATIENTS WITH DIRECT SUPPORT THROUGH OUR PEER-LED TRAINED VOLUNTEER COMMUNITY GROUPS, SUPPORT GROUPS, OUR ONE-ONE-ONE PATIENT NAVIGATOR SUPPORT PROGRAM, AND COMMUNITY OUTREACH ACTIVITIES. FSR PROVIDES DIRECT PATIENT EDUCATION THROUGH FSR'S WEBINAR AND TOWN HALL EDUCATIONAL SERIES, FSR SARC FIGHTER PODCAST. FSR HAS ALSO PROVIDED A SPECIFIC EMPHASIS ON IMPROVING REPRESENTATION IN CLINICAL TRIALS THROUGH OUR IGNORE NO MORE EFFORTS.FSR ALSO PROVIDES CLINICIAN EDUCATION AND SUPPORT THROUGH THE CLINICIAN EDUCATION AND ENGAGEMENT SERIES, PEER CASE REVIEWS, AND THE FSR JOURNAL CLUB. THESE PROGRAMS PROVIDE CLINICIANS WITH CONTINUING MEDICAL EDUCATION CREDITS AND FOSTER BEST PRACTICE SHARING AND OUTCOME IMPROVEMENT STRATEGIES.
FSR PROVIDES RESEARCH FUNDING THROUGH OUR FELLOWSHIP, CARDIAC GRANT, AND PILOT GRANT FUNDING PROGRAM. THROUGH THE FSR CLINICAL STUDIES NETWORK, FSR FUNDS AND FACILITATES A 12 SITE INTERNATIONAL STUDY...
FSR PROVIDES RESEARCH FUNDING THROUGH OUR FELLOWSHIP, CARDIAC GRANT, AND PILOT GRANT FUNDING PROGRAM. THROUGH THE FSR CLINICAL STUDIES NETWORK, FSR FUNDS AND FACILITATES A 12 SITE INTERNATIONAL STUDY SEEKING TO UNDERSTAND THE DIAGNOSIS OF CARDIAC SARCOIDOSIS. FSR HAS ALSO SIGNIFICANTLY INCREASED PARTICIPATION IN THE FSR PATIENT REPORTED OUTCOMES REGISTRY IN ORDER TO INCREASE UNDERSTANDING OF PATIENT'S LIVED EXPERIENCE WITH SARCOIDOSIS.
FSR WORKS DIRECTLY WITH INDUSTRY PARTNERS LEVERAGING ITS EXPERTISE, CONTACTS, THE FSR PATIENT REPORTED OUTCOMES REGISTRY, AND ITS DATABASE IN SUPPORT OF ACADEMIC AND INDUSTRY SPONSORED RESEARCH...
FSR WORKS DIRECTLY WITH INDUSTRY PARTNERS LEVERAGING ITS EXPERTISE, CONTACTS, THE FSR PATIENT REPORTED OUTCOMES REGISTRY, AND ITS DATABASE IN SUPPORT OF ACADEMIC AND INDUSTRY SPONSORED RESEARCH EFFORTS. THROUGH THIS PROGRAM FSR HELPS TO REVIEW PROTOCOLS, CONNECT INDUSTRY WITH POSSIBLE INVESTIGATORS AND RESEARCH SITES, AND SUPPORT THE RECRUITMENT AND ENROLLMENT OF SARCOIDOSIS-RELATED INDUSTRY SPONSORED TRIALS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $13,585,865 | $2,574,104 | +4.3% |
| Expenses | $3,368,016 | $2,402,436 | +0.4% |
| Net Income | $10,217,849 | $171,668 | +58.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| MARY COBB | PRESIDENT | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| HEIDI W JUNK | VICE PRESIDENT (THRU DEC-2024) | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| MICHAEL KAPLAN | TREASURER (THRU DEC-2024) | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| JOEL ROSEN | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| YVETTE C COZIER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| EMERSON RANDY HALL JR | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CALVIN HARRIS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| MICHAEL KLINGHER | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY RAICH | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LOUISE M PERKINS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| CRAIG LIPSET | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| LESLIE SERCHUCK | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| REV MICHAEL A WALROND JR | DIRECTOR (THRU NOV-24) | 1.00 |
Director
|
$0 | $0 | $0 |
| MARY MCGOWAN | PRESIDENT & CEO | 40.00 |
Officer
|
$256,000 | $16,376 | $272,376 |
| TRICHA SHIVAS | CHIEF OF STAFF AND STRATEGY | 40.00 |
Officer
|
$200,600 | $16,556 | $217,156 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $13,585,865 | $3,368,016 | $17,183,158 | $10,217,849 |
| 2023 | $2,574,104 | $2,402,436 | $5,742,895 | $171,668 |
| 2022 | $1,673,599 | $2,027,945 | $4,929,854 | $-354,346 |
| 2021 | $2,385,283 | $1,728,967 | $6,004,041 | $656,316 |
| 2020 | $1,785,472 | $1,389,197 | $5,212,814 | $396,275 |
| 2019 | $2,172,152 | $2,666,891 | $4,488,567 | $-494,739 |
| 2018 | $4,058,860 | $2,454,428 | $4,456,932 | $1,604,432 |
Compare FOUNDATION FOR SARCOIDOSIS RESEARCH with other nonprofits in Illinois and across the country.